TECH historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in TECH.
TECH annual returns by year
Congress trading in TECH
2 members of Congress have disclosed trading TECH — 3 purchases and 1 sale worth an estimated $32,000. Most recent disclosure: Dec 5, 2025.
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
TECH Key Statistics
TECH in plain English
- P/E ratio (62.6) — how many dollars you pay for each $1 of TECH's yearly profit. That's high, so the market expects strong growth (and you're paying up for it).
- ROE (9.03%) — how efficiently the company turns shareholders' money into profit. This is a middling level.
- Profit margin (14.97%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend yield (0.44%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.
TECH stock: frequently asked questions
What is Bio-Techne Corporation's stock price today?
Bio-Techne Corporation (TECH) last traded at $72.61 on the NASDAQ. Over the past 52 weeks the stock has traded between $43.20 and $72.69.
How much would $1,000 invested in TECH 10 years ago be worth today?
A $1,000 investment in Bio-Techne Corporation made 10 years ago would be worth about $2,814 today (dividends reinvested) — a total return of 181%, or 10.9% per year.
Does TECH pay a dividend?
Yes. Bio-Techne Corporation currently pays a dividend yielding about 0.44% per year at today's share price.
What is TECH's P/E ratio?
TECH trades at a trailing price-to-earnings ratio of 62.6, and 31.5 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade TECH stock?
Yes — 2 members of Congress have disclosed trades in TECH under the STOCK Act, totaling 3 purchases and 1 sales worth an estimated $32,000.
What is Bio-Techne Corporation's ticker symbol?
Bio-Techne Corporation trades under the ticker symbol TECH on the NASDAQ.
Compare TECH with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.